EN | TR
E-ISSN: 2602-2974
The Effect of Adjuvant Therapies on the Morbidity and Mortality of Intensive Care Patients with COVID-19
PDF
Cite
Share
Request
Original Research
VOLUME: 18 ISSUE: 1
P: 31-38
March 2020

The Effect of Adjuvant Therapies on the Morbidity and Mortality of Intensive Care Patients with COVID-19

J Turk Soc Intens Care 2020;18(1):31-38
DOI: 10.4274/tybd.galenos.2020.03511
Abdullah Özdemir 1
Başar Erdivanlı 1
Asiye Özdemir 2
Hızır Kazdal 1
Leyla Kazancıoğlu 1
Tolga Koyuncu 1
Ayşe Hızal 2
Tahir Ersöz 2
1. Recep Tayyip Erdoğan Üniversitesi Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, Rize, Türkiye
2. T.C Sağlık Bakanlığı, Recep Tayyip Erdoğan Üniversitesi Eğitim ve Araştırma Hastanesi, Anesteziyoloji ve Reanimasyon Kliniği, Rize, Türkiye
No information available.
No information available
Received Date: 13.07.2020
Accepted Date: 21.09.2020
Publish Date: 14.10.2020
PDF
Cite
Share
Request

ABSTRACT

Objective:

Immune plasma therapy (IPT) is an established therapy that involves transfer of passive immunity. Given the lack of vaccine and specific therapy for Coronavirus diseases-2019 (COVID-19), IPT has been successfully used in intensive care units (ICUs). This study aimed to investigate the effect of IPT and adjuvant therapies on the morbidity and mortality of patients with COVID-19.

Materials and Methods:

Data of patients who were treated in ICUs during the COVID-19 pandemic were retrospectively reviewed. Patient characteristics, dose and duration of adjuvant therapies specific for COVID-19 (IPT, vitamin C, methylprednisolone, n-acetyl cysteine), vital signs, hemodynamic and respiratory function, COVID-19 infection parameters, and outcomes such as morbidities and mortality were recorded.

Results:

Data of five patients with COVID-19 who underwent IPT were analyzed. Three patients without comorbidities recovered and were sent home. One patient with a history of uncontrolled diabetes mellitus died on day 32 of admission in the ICU. Yet another patient with a history of hypertension was tracheotomized and discharged to a palliative care center with a home ventilator because of chronic respiratory insufficiency.

Conclusion:

These results suggest that IPT may have positive effects on COVID-19 infection. However, given the limited number of cases treated in several discrete centers, there is a need for meta-analysis or a randomized clinical trial.

Keywords: COVID-19, intensive care, immune plasma therapy, adjuvant therapy

References

1
T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Bilim kurulu çalışması, covıd-19 (sars-cOV-2 enfeksiyonu) rehberi, 14 Nisan 2020. Available from: URL: https://www.fip.org/files/content/priority-areas/coronavirus/mo-resources/Turkey_SARSCoV2InfectionGuide.pdf
2
Hacıbekiroğlu T, Yiğenoglu TN, Kalpakcı Y. Convalescent (Immune) Plasma  erapy in the Treatment of Critical Patients Infected with SARS-Cov-2. J Biotechnol and Strategic Health Res 2020;1(Özel Sayı):128-34.
3
Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care 2020;24.
4
Draghici S, Nguyen TM, Sonna LA, Ziraldo C, Vanciu RL, Fadel R, et al. COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases. medRxiv doi: 10.1101/2020.05.06.20076687v1
5
Bauer SR, Kapoor A, Rath M, Thomas SA. What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19? Clevel Clin J Med doi: 10.3949/ccjm.87a.ccc046
6
T.C.  Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Covıd-19 İmmün (konvalesan) Plazma Tedarik ve Klinik Kullanım Rehberi, Nisan 2020 Available from: URL: http://etikkurul.gantep.edu.tr/upload/files/COV%C4%B0D-19%20%C4%B0MM%C3%9CN%20PLAZMA%20TEDAR%C4%B0K%20VE%20KULLANIM%20REHBER%C4%B0.pdf
7
Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019-COVID-NET, 14 States, March 1–30, 2020. MMWR 2020;69.
8
Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region-Case Series. N Engl J Med 2020;382:2012-22.
9
Guan WJ, Liang Wh, Zhao Y, Liang Hr, Chen Zs, Li Ym, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547.
10
Coronovirüs Hastalığı 2019 (COVİD 19) ve Akciğer: Göğüs Hastalıkları Uzmanların Bilmesi Gerekenler Türkiye Solunum Araştırmaları Derneği 27 Nisan 2020, Available from: URL: http://www.solunum.org.tr/TusadData/userfiles/file/EJP-EK-SAYI-COVID19-29042020.pdf
11
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017;43:304–77.
12
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526–33.
13
Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care 2020;24.
14
Shen C, Wang Z,  Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020;323:1582-9.
15
Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther 2020;5.
16
Aktoz M, Altay H, Aslanger E, Atalar E, Atar İ, Aytekin V, et al. Türk Kardiyoloji Derneği Uzlaşı Raporu: COVID-19 Pandemisi ve Kardiyovasküler Hastalıklar Konusunda Bilinmesi Gerekenler. Turk Kardiyol Dern Ars 2020;48(Suppl 1):1-87.
17
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020;50:332–4.
18
Fischer JC, Zänker K, Griensven MV, Schneider M, Milles DK, Knoefel WT, et al. The role of passive immunization in the age of SARS CoV 2: an update. Eur J Med Res 2020;25:16.
19
World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020. Available from: URL: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov
20
Biancatelli RMLC, Berrill M, Catravas JD, Marik PE. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19). Front Immunol 2020;11:1451.
21
Fowler AA, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA 2019;322:1261-70.
22
Hemilä H, Chalker E. Vitamin C as a Possible Therapy for COVID-19. Infect Chemother 2020;52:222-3.
23
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5.
24
Liu J, Zheng X, Huang Y, Shan H, Huang J. Successful use of methylprednisolone for treating severe COVID-19. J Allergy Clin Immunol 2020;146:325-7.
25
Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-infl ammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther 2007;20:9-22.
26
Ziehr DR, Alladina J, Petri CR, Maley JH, Moskowitz A, Medoff BD, et al. Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study. Am J Respir Crit Care Med 2020;201:1560-4.
27
Elharrar X, Trigui Y, Dols AM, Touchon F, Martinez S, Prud’homme E, et al. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. JAMA  2020;323:2336-8.
2024 ©️ Galenos Publishing House